메뉴 건너뛰기




Volumn 51, Issue 5, 2007, Pages 1822-1826

Compartmental pharmacokinetic analysis of oral amprenavir with secondary peaks

(20)  Okusanya, Olanrewaju a   Forrest, Alan a   DiFrancesco, Robin a   Bilic, Sanela a   Rosenkranz, Susan b   Para, Michael F c   Adams, Elizabeth d   Yarasheski, Kevin E e   Reichman, Richard C f   Morse, Gene D a   Brizz, Barbara g   Segal, Yoninah h   Walawander, Ann i   Ashton, Courtney i   Ferguson, Elaine j   De Caprariis, Pascal J k   Saah, Alfred J k   Becker, Mark k   Wire, Mary l   Shelton, Mark l  


Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR;

EID: 34248379038     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00570-06     Document Type: Article
Times cited : (25)

References (24)
  • 1
    • 85033517914 scopus 로고
    • Bayesian extension of the minimum AIC procedure of autoregressive model fitting
    • Akaike, H. 1979. Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242.
    • (1979) Biometrika , vol.66 , pp. 237-242
    • Akaike, H.1
  • 2
    • 24044460758 scopus 로고    scopus 로고
    • Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modeling
    • Cremers, S., R. Schoemaker, E. Scholten, J. den Hartigh, J. Konig-Quartel, E. van Kan, L. Paul, and J. de Fijter. 2005. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modeling. Br. J. Clin. Pharmacol. 60:249-256.
    • (2005) Br. J. Clin. Pharmacol , vol.60 , pp. 249-256
    • Cremers, S.1    Schoemaker, R.2    Scholten, E.3    den Hartigh, J.4    Konig-Quartel, J.5    van Kan, E.6    Paul, L.7    de Fijter, J.8
  • 4
    • 0018387530 scopus 로고
    • A program package for simulation and parameter estimation in pharmacokinetic systems
    • D'Argenio, D. Z., and A. Schumitzky. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput. Programs Biomed. 9:115-134.
    • (1979) Comput. Programs Biomed , vol.9 , pp. 115-134
    • D'Argenio, D.Z.1    Schumitzky, A.2
  • 8
    • 24944529235 scopus 로고    scopus 로고
    • Coupling of conjugating enzymes and efflux transporters: Impact on bioavailability and drug interactions
    • Jeong, E. J., X. Liu, X. Jia, J. Chen, and M. Hu. 2005. Coupling of conjugating enzymes and efflux transporters: impact on bioavailability and drug interactions. Curr. Drug Metab. 6:455-468.
    • (2005) Curr. Drug Metab , vol.6 , pp. 455-468
    • Jeong, E.J.1    Liu, X.2    Jia, X.3    Chen, J.4    Hu, M.5
  • 9
    • 0003024589 scopus 로고
    • Guidelines for collection and analysis of pharmacokinetic data
    • W. E. Evans, W. J. Jusko, and J. J. Schentag ed, 3rd ed. Applied Therapeutics, Washington, DC
    • Jusko, W. J. 1992. Guidelines for collection and analysis of pharmacokinetic data, p. 21-43. In W. E. Evans, W. J. Jusko, and J. J. Schentag (ed.), Applied pharmacokinetics, 3rd ed. Applied Therapeutics, Washington, DC.
    • (1992) Applied pharmacokinetics , pp. 21-43
    • Jusko, W.J.1
  • 10
    • 0038103536 scopus 로고    scopus 로고
    • Reverse phase high performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite, M8, ritonavir, and saquinavir in heparinized human plasma
    • Keil, K., V. A. Frerichs, R. DiFrancesco, and G. D. Morse. 2003. Reverse phase high performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite, M8, ritonavir, and saquinavir in heparinized human plasma. Ther. Drug Monit. 25:340-346.
    • (2003) Ther. Drug Monit , vol.25 , pp. 340-346
    • Keil, K.1    Frerichs, V.A.2    DiFrancesco, R.3    Morse, G.D.4
  • 11
    • 0034114537 scopus 로고    scopus 로고
    • Pharmacokinetics, biliary excretion, and tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawley rats
    • Kuchimanchi, K. R., C. Udata, T. P. Johnston, and A. K. Mitra. 2000. Pharmacokinetics, biliary excretion, and tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawley rats. Drug Metab. Dispos. 28:403-408.
    • (2000) Drug Metab. Dispos , vol.28 , pp. 403-408
    • Kuchimanchi, K.R.1    Udata, C.2    Johnston, T.P.3    Mitra, A.K.4
  • 12
    • 0242664896 scopus 로고    scopus 로고
    • Enteric disposition and recycling of flavonoids and ginkgo flavonoids
    • Liu, Y., Y. Liu, Y. Dai, L. Xun, and M. Hu. 2003. Enteric disposition and recycling of flavonoids and ginkgo flavonoids. J. Altern. Complement. Med. 9:631-640.
    • (2003) J. Altern. Complement. Med , vol.9 , pp. 631-640
    • Liu, Y.1    Liu, Y.2    Dai, Y.3    Xun, L.4    Hu, M.5
  • 13
    • 0036349377 scopus 로고    scopus 로고
    • Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications
    • Roberts, M. S., B. M. Magnusson, F. J. Burczynski, and M. Weiss. 2002. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 41:751-790.
    • (2002) Clin. Pharmacokinet , vol.41 , pp. 751-790
    • Roberts, M.S.1    Magnusson, B.M.2    Burczynski, F.J.3    Weiss, M.4
  • 14
    • 0035180518 scopus 로고    scopus 로고
    • Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir
    • Sadler, B. M., C. Gillotin, Y. Lou, J. J. Eron, W. Lang, R. Haubrich, and D. S. Stein. 2001. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir. Antimicrob. Agents Chemother. 45:3663-3668.
    • (2001) Antimicrob. Agents Chemother , vol.45 , pp. 3663-3668
    • Sadler, B.M.1    Gillotin, C.2    Lou, Y.3    Eron, J.J.4    Lang, W.5    Haubrich, R.6    Stein, D.S.7
  • 15
    • 0035174709 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing
    • Sadler, B. M., C. Gillotin, Y. Lou, and D. S. Stein. 2001. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob. Agents Chemother. 45:30-37.
    • (2001) Antimicrob. Agents Chemother , vol.45 , pp. 30-37
    • Sadler, B.M.1    Gillotin, C.2    Lou, Y.3    Stein, D.S.4
  • 16
    • 0032779413 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults
    • Sadler, B. M., C. D. Hanson, G. E. Chittick, W. T. Symonds, and N. S. Roskell. 1999. Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob. Agents Chemother. 43:1686-1692.
    • (1999) Antimicrob. Agents Chemother , vol.43 , pp. 1686-1692
    • Sadler, B.M.1    Hanson, C.D.2    Chittick, G.E.3    Symonds, W.T.4    Roskell, N.S.5
  • 17
  • 18
    • 33644645264 scopus 로고    scopus 로고
    • Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir
    • Shelton, M. J., M. B. Wire, Y. Lou, B. Adamkiewicz, and S. S. Min. 2006. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob. Agents Chemother. 50:928-934.
    • (2006) Antimicrob. Agents Chemother , vol.50 , pp. 928-934
    • Shelton, M.J.1    Wire, M.B.2    Lou, Y.3    Adamkiewicz, B.4    Min, S.S.5
  • 20
    • 0021277886 scopus 로고
    • Alternative approaches to estimation of population pharmacokinetic parameters: Comparison with the nonlinear mixed-effect model
    • Steimer, J. L., A. Mallet, J. L. Golmard, and J. F. Boisvieux. 1984. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. Drug Metab. Rev. 15:265-292.
    • (1984) Drug Metab. Rev , vol.15 , pp. 265-292
    • Steimer, J.L.1    Mallet, A.2    Golmard, J.L.3    Boisvieux, J.F.4
  • 22
    • 0004580383 scopus 로고    scopus 로고
    • A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration
    • Wang, Y., A. Roy, L. Sun, and C. E. Lau. 1999. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab. Dispos. 27:855-859.
    • (1999) Drug Metab. Dispos , vol.27 , pp. 855-859
    • Wang, Y.1    Roy, A.2    Sun, L.3    Lau, C.E.4
  • 23
    • 33645789309 scopus 로고    scopus 로고
    • Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV
    • Wire, M. B., K. L. Baker, L. S. Jones, M. J. Shelton, Y. Lou, G. J. Thomas, and M. M. Berrey. 2006. Ritonavir increases plasma amprenavir (APV) exposure to a similar extent when coadministered with either fosamprenavir or APV. Antimicrob. Agents Chemother. 50:1578-1580.
    • (2006) Antimicrob. Agents Chemother , vol.50 , pp. 1578-1580
    • Wire, M.B.1    Baker, K.L.2    Jones, L.S.3    Shelton, M.J.4    Lou, Y.5    Thomas, G.J.6    Berrey, M.M.7
  • 24
    • 33344460707 scopus 로고    scopus 로고
    • Fosamprenavir: Clinical pharmacokinetics and drug interactions of the amprenavir prodrug
    • Wire, M. B., M. J. Shelton, and S. Studenberg. 2006. Fosamprenavir: clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin. Pharmacokinet. 45:137-168.
    • (2006) Clin. Pharmacokinet , vol.45 , pp. 137-168
    • Wire, M.B.1    Shelton, M.J.2    Studenberg, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.